Fig. 6: Crizotinib exerts antimetastatic activity in vivo.

a Representative in vivo bioluminescence images were obtained 10 min after intraperitoneal injection of D-Luciferin in mice treated with crizotinib (0, 10, or 25 mg/kg) (see also Supplementary Fig. 14a). The radiance unit of photon/s/cm²/sr is the number of photons per second that leave a square centimeter of tissue and radiate into a solid angle of one steradian (sr). b Ex vivo bioluminescence images were measured from various isolated organs (see also Supplemental Fig. 14b). c, d Bioluminescence intensity was quantified for each mouse (a) or isolated lung tissue (b), and the mean value was calculated for each cohort. The data were expressed as the mean ± SEM (n = 5). *p < 0.01. e, f Phospho-Smad3-positive cells were assessed using immunofluorescence microscopic analysis in metastatic tumor tissues. Representative images of immunofluorescence staining (e) and quantification of the percentage of phospho-Smad3-positive cells (f). The data were expressed as the mean ± SEM (n = 160–424 fields from five tissues for each group). ***p < 0.005. g–i Tumor volumes were recorded twice (every other day) for 22 days. g The figures show the mean ± SEM (n = 5). h, i At 22 days after xenograft implantation, the mice were sacrificed to determine tumor volume (h) and weight (i). The figures show the mean ± SEM (n = 5). **p < 0.01. n.s. not significant.